A Phase 3 interventional study of Adalimumab in Psoriatic Arthritis, sponsored by Abbott. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-05-02.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing adalimumab in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 2 of them phase 3. Adalimumab · Arthritis, Psoriatic.
Among the 13 studies testing adalimumab in Arthritis, Psoriatic, this one is the 6th largest by enrollment, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 2nd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 13 studies testing adalimumab in Arthritis, Psoriatic are open now, in 11 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
Tanta University · Sites in Egypt
Ages 18–70
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 87 Arthritis, Psoriatic studies recruiting now, 52 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 108 across the 13 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 6 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
1 of the studies testing adalimumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing adalimumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To further assess the safety and effectiveness of adalimumab 40mg in the treatment PsA who have had an unsatisfactory response or intolerance to prior or ongoing DMARDs
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ACR20 response
Time frame: Week 12
ACR50
Time frame: Week 12
ACR70
Time frame: Week 12
PsARC
Time frame: Week 12
DAS28
Time frame: Week 12
PASI50/75
Time frame: Week 12
HAQ-DI
Time frame: Week 12
PsAQoL
Time frame: Week 12
No study locations are listed for this record.
The record gives a start of May 2006 and a primary completion of May 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab